NO20073224L - Flytende og halvfaste farmasoytiske preparater for oral administrering av et substituert amid - Google Patents
Flytende og halvfaste farmasoytiske preparater for oral administrering av et substituert amidInfo
- Publication number
- NO20073224L NO20073224L NO20073224A NO20073224A NO20073224L NO 20073224 L NO20073224 L NO 20073224L NO 20073224 A NO20073224 A NO 20073224A NO 20073224 A NO20073224 A NO 20073224A NO 20073224 L NO20073224 L NO 20073224L
- Authority
- NO
- Norway
- Prior art keywords
- semi
- liquid
- oral administration
- pharmaceutical preparations
- solid pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63074604P | 2004-11-24 | 2004-11-24 | |
PCT/US2005/041836 WO2006057903A2 (en) | 2004-11-24 | 2005-11-18 | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073224L true NO20073224L (no) | 2007-08-23 |
Family
ID=36498432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073224A NO20073224L (no) | 2004-11-24 | 2007-06-22 | Flytende og halvfaste farmasoytiske preparater for oral administrering av et substituert amid |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070298099A1 (pt) |
EP (1) | EP1817012A2 (pt) |
JP (1) | JP2008521807A (pt) |
KR (1) | KR20070084531A (pt) |
CN (1) | CN101065115A (pt) |
AU (1) | AU2005309808A1 (pt) |
BR (1) | BRPI0518484A2 (pt) |
CA (1) | CA2587733A1 (pt) |
IL (1) | IL183309A0 (pt) |
MX (1) | MX2007006183A (pt) |
NO (1) | NO20073224L (pt) |
RU (1) | RU2007123366A (pt) |
WO (1) | WO2006057903A2 (pt) |
ZA (1) | ZA200703532B (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016203127B2 (en) * | 2005-11-07 | 2018-07-12 | Murty Pharmaceuticals, Inc | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
US9265724B2 (en) * | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
US20160184258A1 (en) * | 2005-11-07 | 2016-06-30 | Murty Pharmaceuticals, Inc. | Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
MY153288A (en) * | 2006-06-28 | 2015-01-29 | Hovid Berhad | An effective pharmaceutical carrier for poorly bioavailable drugs |
WO2008030389A2 (en) * | 2006-09-06 | 2008-03-13 | Merck & Co., Inc. | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
US20090041839A1 (en) * | 2007-05-23 | 2009-02-12 | Beasley Martin W | Pharmaceutical compositions for the treatment of pain |
WO2009024590A2 (en) * | 2007-08-21 | 2009-02-26 | Basilea Pharmaceutica Ag | Antifungal composition |
BRPI0909187A2 (pt) * | 2008-03-20 | 2015-08-04 | Virun Inc | Emulsões incluindo tocoferol de derivados de peg |
US8765661B2 (en) | 2008-03-20 | 2014-07-01 | Virun, Inc. | Compositions containing non-polar compounds |
EP2111854A1 (en) * | 2008-04-22 | 2009-10-28 | Lek Pharmaceuticals D.D. | Self-microemulsifying systems incorporated into liquid core microcapsules |
US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
WO2010019255A1 (en) * | 2008-08-13 | 2010-02-18 | Virun, Inc. | Compositions containing aminoalkanes and aminoalkane derivatives |
WO2010044093A1 (en) * | 2008-10-16 | 2010-04-22 | Strides Arcolab Limited | Formulations containing rifaximin |
WO2011041710A2 (en) * | 2009-10-01 | 2011-04-07 | Martek Biosciences Corporation | Docosahexaenoic acid gel caps |
WO2011119228A1 (en) | 2010-03-23 | 2011-09-29 | Virun, Inc. | Nanoemulsion including sucrose fatty acid ester |
WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
JP2013209294A (ja) * | 2010-07-30 | 2013-10-10 | Meiji Seikaファルマ株式会社 | 液状医薬組成物 |
EP2438911A1 (en) * | 2010-10-08 | 2012-04-11 | LEK Pharmaceuticals d.d. | Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
SG11201404640YA (en) | 2012-02-10 | 2014-09-26 | Virun Inc | Beverage compositions containing non-polar compounds |
ES2763352T3 (es) * | 2013-01-14 | 2020-05-28 | Infirst Healthcare Ltd | Composiciones de solución sólida y uso en inflamación crónica |
AU2014204739B2 (en) * | 2013-01-14 | 2016-08-11 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
BR112015015870B1 (pt) * | 2013-02-04 | 2022-09-27 | Infirst Healthcare Limited | Uso de uma composição farmacêutica |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
KR20170020779A (ko) * | 2014-06-17 | 2017-02-24 | 머크 샤프 앤 도메 비.브이. | 테스토스테론 운데카노에이트의 안정한 제제 |
US10799479B2 (en) | 2015-04-10 | 2020-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of DIM-related indoles |
US10722527B2 (en) * | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
MX2017001714A (es) * | 2017-02-07 | 2018-08-06 | Rhein Siegfried Sa De Cv | Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla. |
WO2018219804A1 (en) * | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Self-microemulsifying drug delivery systems |
ES2943492T3 (es) | 2018-11-30 | 2023-06-13 | Chemocentryx Inc | Formulación de cápsulas |
AU2020270985A1 (en) * | 2019-04-11 | 2021-12-09 | Pfizer Ireland Pharmaceuticals | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
WO2000033862A1 (en) * | 1998-12-11 | 2000-06-15 | Pharmasolutions, Inc. | Self-emulsifying compositions for drugs poorly soluble in water |
JP2000256323A (ja) * | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | 2−オキソキノリン化合物及びその医薬用途 |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
FR2804015B1 (fr) * | 2000-01-21 | 2005-12-23 | Oreal | Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations |
US6562822B2 (en) * | 2000-07-12 | 2003-05-13 | Pharmacia & Upjohn Company | Heterocyle carboxamides as antiviral agents |
FR2818905A1 (fr) * | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
DE10107261B4 (de) * | 2001-02-16 | 2005-03-10 | Merck Patent Gmbh | Pharmazeutische Zusammensetzung |
GB2391471B (en) * | 2002-08-02 | 2005-05-04 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
US8535716B2 (en) * | 2004-04-01 | 2013-09-17 | Tsrl, Inc. | Methods and composition of extended delivery of water insoluble drugs |
US20100216848A1 (en) * | 2007-10-10 | 2010-08-26 | Peresypkin Andrey V | Liquid pharmaceutical compositions for parenteral administration of a substituted amide |
-
2005
- 2005-11-18 CN CNA2005800403069A patent/CN101065115A/zh active Pending
- 2005-11-18 MX MX2007006183A patent/MX2007006183A/es unknown
- 2005-11-18 WO PCT/US2005/041836 patent/WO2006057903A2/en active Application Filing
- 2005-11-18 RU RU2007123366/15A patent/RU2007123366A/ru not_active Application Discontinuation
- 2005-11-18 US US11/667,344 patent/US20070298099A1/en not_active Abandoned
- 2005-11-18 CA CA002587733A patent/CA2587733A1/en not_active Abandoned
- 2005-11-18 KR KR1020077011766A patent/KR20070084531A/ko not_active Application Discontinuation
- 2005-11-18 AU AU2005309808A patent/AU2005309808A1/en not_active Abandoned
- 2005-11-18 JP JP2007543271A patent/JP2008521807A/ja not_active Withdrawn
- 2005-11-18 EP EP05824856A patent/EP1817012A2/en not_active Withdrawn
- 2005-11-18 BR BRPI0518484-3A patent/BRPI0518484A2/pt not_active IP Right Cessation
-
2007
- 2007-05-02 ZA ZA200703532A patent/ZA200703532B/xx unknown
- 2007-05-17 IL IL183309A patent/IL183309A0/en unknown
- 2007-06-22 NO NO20073224A patent/NO20073224L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1817012A2 (en) | 2007-08-15 |
US20070298099A1 (en) | 2007-12-27 |
BRPI0518484A2 (pt) | 2008-11-18 |
WO2006057903A3 (en) | 2006-07-20 |
ZA200703532B (en) | 2008-09-25 |
AU2005309808A1 (en) | 2006-06-01 |
WO2006057903A2 (en) | 2006-06-01 |
RU2007123366A (ru) | 2008-12-27 |
IL183309A0 (en) | 2007-09-20 |
CN101065115A (zh) | 2007-10-31 |
JP2008521807A (ja) | 2008-06-26 |
CA2587733A1 (en) | 2006-06-01 |
KR20070084531A (ko) | 2007-08-24 |
MX2007006183A (es) | 2007-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20073224L (no) | Flytende og halvfaste farmasoytiske preparater for oral administrering av et substituert amid | |
JP6437984B2 (ja) | 経口投与用タペンタドールの水性医薬製剤 | |
US10894039B2 (en) | Amlodipine formulations | |
EA007921B1 (ru) | Лечение атрофии мышц с помощью селективных модуляторов андрогенового рецептора | |
ATE516016T1 (de) | Selbstemulgierende formulierungen von cetp- hemmern | |
AR055363A1 (es) | Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion | |
DE50309547D1 (de) | Stabile creme-zubereitungen von phenyl-pyridonverbindungen für topische anwendung | |
US20240252433A1 (en) | Amlodipine formulations | |
US20040242683A1 (en) | Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl] amino)phenyl] 2-methylpropanethioate | |
NO20043001L (no) | Farmasoytisk formulering omfattende cyklosporin og anvendelse derav | |
JP6753312B2 (ja) | 医療用皮膚外用剤 | |
JP5855349B2 (ja) | 油性製剤 | |
JP2006509038A5 (pt) | ||
RU2699022C1 (ru) | Галеновая композиция, включающая лекарственное средство для местного применения | |
JPH0725770A (ja) | 経皮吸収性抗ウイルス剤 | |
FR2838653B1 (fr) | Procede de preparation d'une emulsion par dilution d'un concentre emulsionnable comprenant un copolymere amphiphile | |
Kinget et al. | Absorption characteristics of novel 8-MOP semi-solid-lipid-matrix formulations: In vitro-in vivo correlation | |
JP2019119684A (ja) | 外用組成物 | |
JP7499024B2 (ja) | 外用組成物 | |
JP7499023B2 (ja) | 外用組成物 | |
JP5778964B2 (ja) | 油性製剤 | |
JP2002241311A (ja) | 界面活性剤を含む医薬組成物 | |
WO2007110876A3 (en) | Novel sulfonanilide derivatives, pharmaceutical compositions comprising the same and process thereof | |
WO2019131650A1 (ja) | 外用組成物 | |
JP2019119685A (ja) | 外用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |